OS Therapies Incorporated (OSTX)

NYSEAMERICAN: OSTX · Real-Time Price · USD
1.650
-0.020 (-1.20%)
Jul 11, 2025, 9:44 AM - Market open
-1.20%
Market Cap 48.96M
Revenue (ttm) n/a
Net Income (ttm) -13.27M
Shares Out 29.67M
EPS (ttm) -0.82
PE Ratio n/a
Forward PE 3.08
Dividend n/a
Ex-Dividend Date n/a
Volume 91,908
Open 1.700
Previous Close 1.670
Day's Range 1.640 - 1.700
52-Week Range 1.120 - 7.000
Beta n/a
Analysts Strong Buy
Price Target 18.00 (+990.91%)
Earnings Date Aug 14, 2025

About OSTX

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 a... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Aug 1, 2024
Employees 5
Stock Exchange NYSEAMERICAN
Ticker Symbol OSTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 3 analysts, the average rating for OSTX stock is "Strong Buy." The 12-month stock price target is $18.0, which is an increase of 990.91% from the latest price.

Price Target
$18.0
(990.91% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

OS Therapies Provides Clinical & Global Regulatory Updates

End of Phase 2 Meeting with FDA scheduled for August 27, 2025 to review OST-HER2 recurrent, pulmonary metastatic osteosarcoma program Scientific Advice Meetings confirmed with global regulators in maj...

1 day ago - Newsfile Corp

OS Therapies Granted End of Phase 2 Meeting by US FDA for OST-HER2 Program in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced it...

8 days ago - Business Wire

OS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor Osteosarcoma Conference

NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced po...

11 days ago - Business Wire

OS Therapies Receives Positive FDA Meeting Feedback on Regulatory Pathway for Accelerated Approval of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma

NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced th...

17 days ago - Business Wire

OS Therapies Announces Warrant Exercise Inducement & Exchange Offer

NEW YORK--(BUSINESS WIRE)--OS Therapies Inc. (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announc...

17 days ago - Business Wire

OS Therapies Partners with EVERSANA for the U.S. Commercialization of OST-HER2 in Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma

NEW YORK and CHICAGO , June 10, 2025 /PRNewswire/ -- OS Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology...

4 weeks ago - PRNewsWire

OS Therapies Submits Request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the Prevention of Metastases in Recurrent, Fully-Resected, Lung Metastatic Pediatric Osteosarcoma

NEW YORK--(BUSINESS WIRE)--OS Therapies Inc. (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced ...

5 weeks ago - Business Wire

OS Therapies Reports First Quarter 2025 Financial Results and Provides Business Update

NEW YORK--(BUSINESS WIRE)--OS Therapies Inc. (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported f...

2 months ago - Business Wire

OS Therapies Forms Subsidiary OS Animal Health to Commercialize OST-HER2 for Canine Osteosarcoma

NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced th...

2 months ago - Business Wire

OS Therapies Announces Issuance of U.S. Patent #12,239,738 Protecting Commercial Manufacturing Market Exclusivity for OST-HER2 in Rare Pediatric Cancer Osteosarcoma and Full Listeria Cancer Immunotherapy Platform into 2040

NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced th...

2 months ago - Business Wire

Emmy-Winning Series Debuts Trailer for "Shelter Me: The Cancer Pioneers" Offering A Hopeful Look at Breakthrough Cancer Therapies

LOS ANGELES--(BUSINESS WIRE)--The official trailer for “Shelter Me: The Cancer Pioneers” has just dropped, giving audiences a moving first look at the groundbreaking new documentary that follows the e...

2 months ago - Business Wire

OS Therapies FDA Meeting Request Granted

NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced th...

2 months ago - Business Wire

OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans

NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced po...

3 months ago - Business Wire

OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals

NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced th...

3 months ago - Business Wire

OS Therapies Requests Meeting with FDA to Gain Agreement on Surrogate Endpoint(s) for Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma

NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced th...

3 months ago - Business Wire

OS Therapies to Host Analyst Day at NYSE on April 7, 2025

NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced th...

3 months ago - Business Wire

OS Therapies Reports Full Year 2024 Financial Results and Provides Business Update

NEW YORK--(BUSINESS WIRE)--OS Therapies Inc. (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported f...

3 months ago - Business Wire

OS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate OST-HER2 for Human Osteosarcoma

NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today provided a r...

3 months ago - Business Wire

OS Therapies' OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers

NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced th...

3 months ago - Business Wire

OS Therapies to Attend The Jones Healthcare and Technology Innovation Conference

NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced th...

4 months ago - Business Wire

OS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma Conference

NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that i...

4 months ago - Business Wire

OS Therapies Schedules United Kingdom's Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma

NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that i...

4 months ago - Business Wire

Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FLORIDA / ACCESS Newswire / February 28, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and OS Therapies Inc. (NYSE American:OSTX) on the ...

Other symbols: CLDI
4 months ago - Accesswire

Join OS Therapies' Exclusive Live Investor Webinar and Q&A Session on February 27

NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, is pleased to inv...

4 months ago - Business Wire

OS Therapies Forms Subsidiary OS Drug Conjugates and Initiates Review of Strategic Options for its tunable ADC & Drug Conjugates Platforms

NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, announced the formatio...

4 months ago - Business Wire